63 related articles for article (PubMed ID: 24248544)
21. Association between fibroblast growth factor receptor 4 Gly388Arg polymorphism and ischaemic stroke.
Zhang HF; Zhao KJ; Yang PF; Fang YB; Zhang YH; Liu JM; Huang QH
J Int Med Res; 2012; 40(5):1708-14. PubMed ID: 23206452
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast growth factor receptor 4 polymorphisms and susceptibility to coronary artery disease.
Ma L; Zhang H; Han C; Tong D; Zhang M; Yao Y; Luo Y; Liu X
DNA Cell Biol; 2012 Jun; 31(6):1064-9. PubMed ID: 22313031
[TBL] [Abstract][Full Text] [Related]
23. FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer.
Fang HM; Tian G; Zhou LJ; Zhou HY; Fang YZ
Acta Pharmacol Sin; 2013 Apr; 34(4):549-54. PubMed ID: 23524567
[TBL] [Abstract][Full Text] [Related]
24. FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer.
Liu R; Li J; Xie K; Zhang T; Lei Y; Chen Y; Zhang L; Huang K; Wang K; Wu H; Wu M; Nice EC; Huang C; Wei Y
Cancer Res; 2013 Oct; 73(19):5926-35. PubMed ID: 23943801
[TBL] [Abstract][Full Text] [Related]
25. Fibroblast growth factor receptors, developmental corruption and malignant disease.
Kelleher FC; O'Sullivan H; Smyth E; McDermott R; Viterbo A
Carcinogenesis; 2013 Oct; 34(10):2198-205. PubMed ID: 23880303
[TBL] [Abstract][Full Text] [Related]
26. Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer.
Fawdar S; Trotter EW; Li Y; Stephenson NL; Hanke F; Marusiak AA; Edwards ZC; Ientile S; Waszkowycz B; Miller CJ; Brognard J
Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12426-31. PubMed ID: 23836671
[TBL] [Abstract][Full Text] [Related]
27. Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma.
Charbonneau B; Vogel RI; Manivel JC; Rizzardi A; Schmechel SC; Ognjanovic S; Subramanian S; Largaespada D; Weigel B
Hum Pathol; 2013 Sep; 44(9):1918-26. PubMed ID: 23664540
[TBL] [Abstract][Full Text] [Related]
28. The involvement of fibroblast growth factor receptor signaling pathways in dermatofibroma and dermatofibrosarcoma protuberans.
Ishigami T; Hida Y; Matsudate Y; Murao K; Kubo Y
J Med Invest; 2013; 60(1-2):106-13. PubMed ID: 23614918
[TBL] [Abstract][Full Text] [Related]
29. B-cell receptor pathobiology and targeting in NHL.
Macias-Perez IM; Flinn IW
Curr Oncol Rep; 2012 Oct; 14(5):411-8. PubMed ID: 22865093
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: a case control study.
Zhu Q; Liu T
Mol Biol Rep; 2012 Sep; 39(9):8679-85. PubMed ID: 22696188
[TBL] [Abstract][Full Text] [Related]
31. Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma.
Yang Y; Zhou Y; Lu M; An Y; Li R; Chen Y; Lu DR; Jin L; Zhou WP; Qian J; Wang HY
Mol Carcinog; 2012 Jul; 51(7):515-21. PubMed ID: 21656577
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma.
Liu Y; He Z; Feng D; Shi G; Gao R; Wu X; Song W; Yuan W
DNA Cell Biol; 2011 Dec; 30(12):1051-5. PubMed ID: 21612409
[TBL] [Abstract][Full Text] [Related]
33. Lysyl oxidase G473A polymorphism is associated with increased risk of coronary artery diseases.
Ma L; Song H; Zhang M; Zhang D
DNA Cell Biol; 2011 Dec; 30(12):1033-7. PubMed ID: 21612403
[TBL] [Abstract][Full Text] [Related]
34. CD86 + 1057G/A polymorphism and susceptibility to osteosarcoma.
Wang W; Song H; Liu J; Song B; Cao X
DNA Cell Biol; 2011 Nov; 30(11):925-9. PubMed ID: 21563968
[TBL] [Abstract][Full Text] [Related]
35. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor.
Frullanti E; Berking C; Harbeck N; Jézéquel P; Haugen A; Mawrin C; Parise O; Sasaki H; Tsuchiya N; Dragani TA
Eur J Cancer Prev; 2011 Jul; 20(4):340-7. PubMed ID: 21412156
[TBL] [Abstract][Full Text] [Related]
36. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression.
Wang J; Yu W; Cai Y; Ren C; Ittmann MM
Neoplasia; 2008 Aug; 10(8):847-56. PubMed ID: 18670643
[TBL] [Abstract][Full Text] [Related]
37. Cellular signaling by fibroblast growth factor receptors.
Eswarakumar VP; Lax I; Schlessinger J
Cytokine Growth Factor Rev; 2005 Apr; 16(2):139-49. PubMed ID: 15863030
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology.
Müller AM; Ihorst G; Mertelsmann R; Engelhardt M
Ann Hematol; 2005 Jan; 84(1):1-12. PubMed ID: 15480663
[TBL] [Abstract][Full Text] [Related]
39. CXCR5-transduced bone marrow-derived dendritic cells traffic to B cell zones of lymph nodes and modify antigen-specific immune responses.
Wu MT; Hwang ST
J Immunol; 2002 May; 168(10):5096-102. PubMed ID: 11994462
[TBL] [Abstract][Full Text] [Related]
40. Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique.
Takahashi A; Sasaki H; Kim SJ; Kakizoe T; Miyao N; Sugimura T; Terada M; Tsukamoto T
Biochem Biophys Res Commun; 1999 Apr; 257(3):855-9. PubMed ID: 10208873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
